Saturday, August 2, 2025

Latest

Therma Bright Expects Rapid Antigen Saliva Test Study To Conclude This Month

Therma Bright (TSXV: THRM) this morning provided a brief update to investors on the status of its clinical study. The study is currently looking to evaluate its COVID-19 rapid antigen saliva test for performance.

The clinical performance study being conducted on the test is reportedly still underway, with the study expected to be completed this month. The study is currently looking to utilize up to 300 participants to determine the tests effectiveness at detecting the virus.

Somewhat ironically, the performance testing of the rapid antigen saliva test has been delayed due to the current wave of the virus overwhelming the firms clinics and labs with PCR testing. The strong demand for testing services has slowed down the time between receiving lab-based tests and cross referencing the results with results from the saliva tests.

In commenting on the results seen to date, Rob Fia, CEO of Therma Bright stated, “Current results are very promising, as we look to be the first COVID-19 rapid antigen saliva test to receive FDA Emergency Use Authorization.”

Therma Bright last traded at $0.37 on the TSX Venture.


Information for this briefing was found via Sedar and Therma Bright Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Therma Bright Ends Arrangement With Torian Biosciences, Assumes 100% Control Of Saliva Rapid Test

Therma Bright (TSXV: THRM) has taken back control of the research and development, regulatory, manufacturing...

Monday, January 25, 2021, 07:52:26 AM

Therma Bright Development Partner Discovers Detection Molecule For COVID-19 Test

Therma Bright Inc (TSXV: THRM) this morning announced that its development partner for its COVID-19...

Thursday, September 3, 2020, 09:39:35 AM

Therma Bright Improves COVID-19 Rapid Saliva Antigen Test To 86% Sensitivity, 100% Specificity

Therma Bright Inc (TSXV: THRM) this afternoon halted its equity from trading for the dying...

Monday, January 18, 2021, 04:22:30 PM